Company Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies.
The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease.
Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.
The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products.
Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Dr. Alfred W. Sandrock Jr., M.D., Ph.D. |
Contact Details
Address: 75 Sidney Street Cambridge, Massachusetts United States | |
| Website | https://www.voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001640266 |
| CUSIP Number | 92915B106 |
| ISIN Number | US92915B1061 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer |
| Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer |
| Robin Swartz | Chief Business Officer & Chief Operating Officer |
| Dr. Guangping Gao Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Dr. Phillip D. Zamore Ph.D. | Founder & Member of Scientific Advisory Board |
| Michelle Quinn Smith | Chief Human Resources Officer |
| Todd Carter Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 26, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 03, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Sep 05, 2024 | 8-K | Current Report |
| Aug 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 06, 2024 | S-8 | Filing |